First-line immune-chemotherapy combination for squamous NSCLC is already a reality

Lizza E. L. Hendriks; Jessica Menis; Jordi Remon

doi:10.21037/tlcr.2020.03.36

First-line immune-chemotherapy combination for squamous NSCLC is already a reality

Lizza E. L. Hendriks^*, Jessica Menis, Jordi Remon

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

52 Downloads (Pure)

Original language	English
Pages (from-to)	819-823
Number of pages	5
Journal	Translational Lung Cancer Research
Volume	9
Issue number	3
DOIs	https://doi.org/10.21037/tlcr.2020.03.36
Publication status	Published - Jun 2020

Keywords

CELL LUNG-CANCER
OPEN-LABEL
PEMBROLIZUMAB

Access to Document

10.21037/tlcr.2020.03.36Licence: CC BY-NC-ND

Full TextFinal published version, 165 KBLicence: Taverne

Cite this

@article{012c1eb8262049f4bf5c8d94ba4ae04c,

title = "First-line immune-chemotherapy combination for squamous NSCLC is already a reality",

keywords = "CELL LUNG-CANCER, OPEN-LABEL, PEMBROLIZUMAB",

author = "Hendriks, {Lizza E. L.} and Jessica Menis and Jordi Remon",

year = "2020",

month = jun,

doi = "10.21037/tlcr.2020.03.36",

language = "English",

volume = "9",

pages = "819--823",

journal = "Translational Lung Cancer Research",

issn = "2218-6751",

publisher = "AME Publishing Company",

number = "3",

}

TY - JOUR

T1 - First-line immune-chemotherapy combination for squamous NSCLC is already a reality

AU - Hendriks, Lizza E. L.

AU - Menis, Jessica

AU - Remon, Jordi

PY - 2020/6

Y1 - 2020/6

KW - CELL LUNG-CANCER

KW - OPEN-LABEL

KW - PEMBROLIZUMAB

U2 - 10.21037/tlcr.2020.03.36

DO - 10.21037/tlcr.2020.03.36

M3 - Editorial

C2 - 32676345

SN - 2218-6751

VL - 9

SP - 819

EP - 823

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

IS - 3

ER -